Wave Life Sciences’ earlier obesity trial disappointment—described as debated and ultimately stock-denting—continued to reverberate in sector conversations about INHBE and activin E pathway strategies. The update framed how firms working in related biology are now under closer scrutiny as investors weigh whether the signal translates to a viable mechanism and development path.